Randomized, double-blind phase 3 study evaluating neoadjuvant platinum-based chemotherapy with perioperative pembrolizumab or placebo in resectable stage IIB or IIIA NSCLC: KEYNOTE-671.

被引：17
|
作者：
Fernando, Hiran C.
Yang, Jing
Ferraro, Geri L.
Keller, Steven M.
机构：
[1] INOVA Fairfax Med Campus, Dept Surg, Falls Church, VA USA
[2] INOVA Fairfax Med Campus, Dept Thorac Surg, Falls Church, VA USA
[3] Merck & Co Inc, Kenilworth, NJ USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.TPS8583
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS8583
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Pembrolizumab vs Platinum-Based Chemotherapy for PD-L1+NSCLC: Phase 3, Randomized, Open-Label KEYNOTE-042 (NCT02220894)
    Lopes, Gilberto De Lima
    Wu, Yi-Long
    Sadowski, Sara
    Zhang, Jin
    Rangwala, Reshma
    Kush, Debra
    Mok, Tony
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (10) : S244 - S245
  • [22] ARIEL3: PHASE 3, RANDOMISED, DOUBLE-BLIND STUDY OF RUCAPARIB VS PLACEBO FOLLOWING RESPONSE TO PLATINUM-BASED CHEMOTHERAPY FOR RECURRENT OVARIAN CARCINOMA (OC)
    Ledermann, J. A.
    Oza, A. M.
    Lorusso, D.
    Aghajanian, C.
    Oaknin, A.
    Dean, A.
    Colombo, N.
    Weberpals, J. I.
    Clamp, A.
    Scambia, G.
    Leary, A.
    Holloway, R. W.
    O'Malley, D. M.
    Cameron, T.
    Maloney, L.
    Goble, S.
    Lin, K. K.
    Sun, J.
    Giordano, H.
    Coleman, R. L.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2017, 27 : 10 - 11
  • [23] ARIEL3: PHASE 3, RANDOMISED, DOUBLE-BLIND STUDY OF RUCAPARIB VS PLACEBO FOLLOWING RESPONSE TO PLATINUM-BASED CHEMOTHERAPY FOR RECURRENT OVARIAN CARCINOMA (OC)
    Ledermann, J. A.
    Oza, A. M.
    Lorusso, D.
    Aghajanian, C.
    Oaknin, A.
    Dean, A.
    Colombo, N.
    Weberpals, J. I.
    Clamp, A.
    Scambia, G.
    Leary, A.
    Holloway, R. W.
    O'Malley, D. M.
    Cameron, T.
    Maloney, L.
    Goble, S.
    Lin, K. K.
    Sun, J.
    Giordano, H.
    Coleman, R. L.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2017, 27 : 1972 - 1973
  • [24] KEYNOTE-756: A randomized, double-blind, phase III study of pembrolizumab or placebo with neoadjuvant chemotherapy and adjuvant endocrine therapy for high-risk, early-stage, ER+/HER2-breast cancer
    Cardoso, F.
    Bardia, A.
    Andre, F.
    Cescon, D. W.
    McArthur, H.
    Telli, M.
    Loi, S.
    Cortes, J.
    Schmid, P.
    Harbeck, N.
    Denkert, C.
    Jackisch, C.
    Jia, L.
    Hirshfield, K.
    Karantza, V.
    ANNALS OF ONCOLOGY, 2019, 30
  • [25] ARIEL3: A phase 3, randomised, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian carcinoma (OC)
    Ledermann, J.
    Oza, A. M.
    Lorusso, D.
    Aghajanian, C.
    Oaknin, A.
    Dean, A.
    Colombo, N.
    Weberpals, J.
    Clamp, A.
    Scambia, G.
    Leary, A.
    Holloway, R.
    O'Malley, D. M.
    Cameron, T.
    Maloney, L.
    Goble, S.
    Lin, K. K.
    Sun, J.
    Giordano, H.
    Coleman, R.
    ANNALS OF ONCOLOGY, 2017, 28
  • [26] Pembrolizumab with platinum-based chemotherapy with or without epacadostat as first-line treatment for metastatic non-small cell lung cancer: a randomized, partially double-blind, placebo-controlled phase II study
    Boyer, Michael
    Hui, Rina
    Urban, Damien
    Clingan, Philip
    Su, Wu-Chou
    Devaux, Celine
    Gadgeel, Shirish
    Garassino, Marina
    Leopold, Lance
    Daniel, Jeannie
    Munteanu, Mihaela C.
    Samkari, Ayman
    Luo, Yiwen
    Abreu, Delvys Rodriguez
    BMC CANCER, 2024, 23 (SUPPL 1)
  • [27] KEYNOTE-826: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF PEMBROLIZUMAB PLUS CHEMOTHERAPY FOR FIRST-LINE TREATMENT OF PERSISTENT, RECURRENT, OR METASTATIC CERVICAL CANCER
    Tewari, K.
    Caceres, M. V.
    Alexandre, J.
    Monk, B.
    Fehm, T.
    Colombo, N.
    Hasegawa, K.
    Dubot, C.
    Li, J. J.
    Stein, K.
    Keefe, S.
    Shapira-Frommer, R.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2019, 29 : A162 - A162
  • [28] KEYNOTE-355: Final results from a randomized, double-blind phase III study of first-line pembrolizumab plus chemotherapy vs placebo plus chemotherapy for metastatic TNBC
    Cortes, J.
    Cescon, D. W.
    Rugo, H. S.
    Im, S-A.
    Yusof, M. Md
    Gallardo, C.
    Lipatov, O.
    Barrios, C. H.
    Perez-Garcia, J.
    Iwata, H.
    Masuda, N.
    Otero, M. Torregroza
    Gokmen, E.
    Loi, S.
    Guo, Z.
    Zhou, X.
    Karantza, V.
    Pan, W.
    Schmid, P.
    ANNALS OF ONCOLOGY, 2021, 32 : S1289 - S1290
  • [29] MATTERHORN: Efficacy and safety of neoadjuvant-adjuvant durvalumab and FLOT chemotherapy in resectable gastric and gastroesophageal junction cancer - a randomized, double-blind, placebo-controlled, phase 3 study
    Janjigian, Yelena
    Van Cutsem, Eric
    Muro, Kei
    Wainberg, Zev
    Al-Batran, Salah-Eddin
    Hyung, Woo Jin
    Molena, Daniela
    Evans, Brent
    Ruscica, Dario
    Robbins, Scott H.
    Negro, Alejandra
    Tabernero, Josep
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 94 - 94
  • [30] Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study
    Rudin, Charles M.
    Awad, Mark M.
    Navarro, Alejandro
    Gottfried, Maya
    Peters, Solange
    Csoszi, Tibor
    Cheema, Parneet K.
    Rodriguez-Abreu, Delvys
    Wollner, Mirjana
    Yang, James Chih-Hsin
    Mazieres, Julien
    Orlandi, Francisco J.
    Luft, Alexander
    Gumus, Mahmut
    Kato, Terufumi
    Kalemkerian, Gregory P.
    Luo, Yiwen
    Ebiana, Victoria
    Pietanza, M. Catherine
    Kim, Hye Ryun
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (21) : 2369 - +
12345